Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Morris

Nurse Practitioner, Primary Care La Follette, TN Nurse Practitioner

NPI 1639143258 CMS profile 11156511

130 Independence Ln, La Follette, TN 37766

Open in the dashboard

General payments

$5,430

114 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Morris of La Follette, TN is reported in the CMS Open Payments database as having received $5,430 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $714 13
2024 General $926 21
2023 General $1,418 23
2022 General $973 27
2021 General $1,398 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Morris
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Mary Morris were reported at $714. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Mary Morris Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,398 $137 $39–$445 $132
2022 $973 $139 $44–$421 $149
2023 $1,418 $163 $53–$481 $160
2024 $926 $176 $54–$511 $164
2025 $714 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Corcept Therapeutics $1,205 21 payments
  2. AstraZeneca Pharmaceuticals LP $1,013 14 payments
  3. Novo Nordisk Inc $945 25 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $366 8 payments
  5. GlaxoSmithKline, LLC. $243 4 payments
  6. Janssen Pharmaceuticals, Inc $225 3 payments
  7. CeQur Corporation $177 2 payments
  8. Xeris Pharmaceuticals, Inc. $174 4 payments
  9. Medtronic, Inc. $136 5 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $126 2 payments
  11. Other $822 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,412 113 payments
  2. Education $18 1 payment
Products named General payments · program years 2021–2025
  1. Korlym $1,205 21 payments
  2. Ozempic $776 21 payments
  3. RYBELSUS $393 17 payments
  4. BREZTRI $368 7 payments
  5. FARXIGA $366 6 payments
  6. Kerendia $366 8 payments
  7. LOKELMA $250 2 payments
  8. XARELTO $225 3 payments
  9. CeQur Simplicity $177 2 payments
  10. RECORLEV $142 2 payments
  11. Other $1,280 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

6,322

Median for Nurse Practitioner: 389

Drug cost

$819,951

Median for Nurse Practitioner: $21,885

Branded share of claims

23.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 105 $119,555
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 104 $118,589
Ozempic Semaglutide Brand 57 $79,997
Eliquis Apixaban Brand 72 $61,590
Trulicity Dulaglutide Brand 30 $55,901
Farxiga Dapagliflozin Propanediol Brand 54 $54,454
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 47 $41,164
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 32 $32,238
Glyxambi Empagliflozin/Linagliptin Brand 33 $29,764
Mounjaro Tirzepatide Brand 21 $22,244

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$2,087

Medicare's payments for the services billed

Medicare patients

58

Average age 70

Services billed

200

32 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 55%
Depression 34%
Arthritis 34%
Ischemic heart disease 29%
Chronic kidney disease 28%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $294
$294 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $159
$159 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $122
$122 — —
RYBELSUS
  • Novo Nordisk Inc $21
$21 — —
RECORLEV
  • Xeris Pharmaceuticals, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record